Moderna, Inc.
Biotechnology and mRNA TherapeuticsFounded 2010- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
Moderna, Inc.
Company History
Founded 2010 in Cambridge, Massachusetts
Last reviewed: 2025-07-15 · By Swet Parvadiya
Moderna, Inc. is a publicly traded biotechnology company founded in 2010 and headquartered in Cambridge, Massachusetts. The origins of Moderna trace back to 2005, when Hungarian biochemist Katalin Karikó and American immunologist Drew Weissman at the University of Pennsylvania published foundational research demonstrating that modified mRNA could evade the body's inflammatory response, solving the key obstacle that had prevented mRNA therapeutics from reaching clinical application. In September 2010, Afeyan, Langer, Rossi, Springer, and Harvard cardiovascular scientist Kenneth Chien founded Moderna Therapeutics, taking the name from a combination of modified and RNA.
Derrick Rossi served as a co-founder of Moderna and remained involved in the company's early scientific direction before departing to pursue other ventures. His discovery of modified mRNA reprogramming provided the initial intellectual property that attracted Flagship Pioneering's investment. Rossi later founded other biotechnology companies including Convelo Therapeutics, focused on remyelination therapies for multiple sclerosis. His scientific contributions to mRNA technology were recognized when the Karikó-Weissman foundational research, which enabled Rossi's work, was awarded the Nobel Prize in Physiology or Medicine in 2023. Rossi's role in Moderna's founding illustrates how academic breakthroughs can be translated into commercial enterprises when combined with venture capital and entrepreneurial vision. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.
Robert Langer has served on Moderna's board of directors since its founding and has been instrumental in guiding the company's scientific strategy and partnerships. His laboratory at MIT continues to conduct foundational research in drug delivery, tissue engineering, and nanotechnology, with more than 300 students and postdoctoral researchers trained under his supervision. Langer has received numerous awards including the National Medal of Science, the National Medal of Technology and Innovation, and the Charles Stark Draper Prize. His involvement in Moderna provided credibility with investors and scientific collaborators, and his network of academic and industry relationships facilitated partnerships that accelerated the company's development. Langer's continued board service reflects his ongoing commitment to the company's mission of transforming mRNA science into medicines. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.
Noubar Afeyan has served as Moderna's chairman since its founding and has been the architect of the company's strategic vision and capital structure. Under his leadership, Flagship Pioneering has built a portfolio of platform biotechnology companies that leverage scientific breakthroughs to create new therapeutic modalities. Afeyan has been instrumental in Moderna's financing strategy, including the 2018 IPO that raised $604 million and valued the company at $7.5 billion, and the subsequent capital raises that funded pandemic-scale manufacturing expansion. His vision of Moderna as a platform company rather than a product company has shaped the company's strategy of maintaining a broad pipeline across multiple therapeutic areas. Afeyan's continued involvement provides strategic continuity and access to Flagship's network of scientific and financial resources. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.
Kenneth Chien served as a co-founder and early scientific advisor to Moderna, contributing to the company's initial pipeline strategy in cardiovascular and rare disease therapeutics. Chien later departed from day-to-day involvement but remained a shareholder. His scientific contributions to cardiovascular biology have been recognized through numerous awards and leadership positions, including founding director of the Harvard Stem Cell Institute Cardiovascular Program. Chien's involvement in Moderna's founding illustrates how academic scientists with domain expertise can translate their research into commercial ventures when combined with platform technology and entrepreneurial leadership. His continued support for the company reflects his belief in the long-term potential of mRNA therapeutics for cardiovascular disease. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.
Katalin Karikó and Drew Weissman at the University of Pennsylvania publish foundational research demonstrating that modified nucleosides in mRNA can evade the body's inflammatory response, solving the key obstacle preventing mRNA therapeutics from clinical application. This discovery, later recognized with the 2023 Nobel Prize in Physiology or Medicine, provides the scientific foundation for all subsequent mRNA vaccine and therapeutic development. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Derrick Rossi, Robert Langer, Noubar Afeyan, Kenneth Chien, and Timothy Springer found Moderna Therapeutics in September 2010, with Flagship Pioneering providing seed funding and incubation. The company's name derives from modified RNA, reflecting its core technology platform. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Stéphane Bancel, former CEO of bioMérieux and executive at Eli Lilly, joins Moderna as founding CEO, bringing pharmaceutical commercial experience to the scientific founding team. Bancel's appointment signals the company's ambition to become a fully integrated pharmaceutical company rather than a technology licensor. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna emerges from two years of stealth operation with a $40 million Series A financing, revealing its mRNA platform technology to the public for the first time. The company announces plans to develop mRNA therapeutics for rare diseases, cardiovascular disease, and oncology. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna signs a strategic partnership with AstraZeneca worth up to $420 million to develop mRNA therapeutics for cardiovascular, metabolic, and renal diseases. The partnership validates Moderna's platform and provides non-dilutive funding for early development programs. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna enters a strategic collaboration with Merck worth up to $450 million to develop personalized cancer vaccines using mRNA technology. The partnership focuses on encoding patient-specific neoantigens to stimulate anti-tumor immune responses, a approach that would later yield promising Phase 2 data. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna completes its initial public offering on the Nasdaq, raising $604 million and achieving a valuation of $7.5 billion, the largest biotech IPO at the time. The IPO funds the company's pivot from rare diseases to infectious disease vaccines, reflecting the platform's speed advantage for pandemic response. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna publishes Phase 1 data for its cytomegalovirus vaccine mRNA-1647 in the New England Journal of Medicine, demonstrating that mRNA vaccines could induce robust immune responses in humans. The data validates the platform's clinical viability and supports the company's expansion into larger infectious disease programs. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna selects mRNA-1273 as its COVID-19 vaccine candidate on January 13, 2020, just two days after the SARS-CoV-2 sequence was published. The vaccine enters Phase 1 trial on March 16, 2020, and receives FDA Emergency Use Authorization on December 18, 2020, just 11 months after sequence selection, shattering all vaccine development records. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna's COVID-19 vaccine Spikevax generates $17.7 billion in annual revenue in 2021, making it one of the best-selling pharmaceutical products in history. The company's market capitalization exceeds $180 billion, and Moderna becomes a household name globally. The vaccine is authorized in more than 70 countries. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna reports $18.4 billion in revenue for 2022, a modest decline from 2021, as government advance purchase agreements transition to commercial procurement. The company begins to diversify its pipeline, announcing programs in latent viruses, rare diseases, and immuno-oncology. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna's revenue falls to $6.8 billion in 2023, a 63% decline, as the COVID vaccine market transitions from pandemic to endemic demand. The company announces plans to reduce costs and diversify beyond COVID vaccines, while maintaining its manufacturing infrastructure for seasonal production. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
The FDA approves mRESVIA (mRNA-1345) for RSV prevention in adults 60 and older, marking Moderna's first non-COVID product approval. The company also reports revenue of $3.2 billion for 2024, a further 53% decline, and announces a $1.5 billion cost-reduction program. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna reports $1.9 billion in revenue for 2025, a 40% decline, but reduces operating expenses by $2.2 billion, exceeding targets. The company launches mNEXSPIKE, its next-generation COVID vaccine, and expands mRESVIA to high-risk adults 18-59. The workforce is reduced by 10% to fewer than 5,000 employees. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna announces that its cytomegalovirus vaccine mRNA-1647 failed to meet its Phase 3 primary endpoint in October 2025, eliminating a potential blockbuster and forcing pipeline prioritization. The failure demonstrates the risks of platform-based drug development. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
The FDA issues a Refusal-to-File letter for Moderna's seasonal flu vaccine mRNA-1010, requiring additional efficacy data before resubmission. The delay pushes potential approval into 2026 or 2027, creating uncertainty around the company's near-term revenue diversification. This milestone shaped Moderna's strategic trajectory and contributed to the company's evolution in the biotechnology industry.
Moderna acquired Carmot Therapeutics for $250 million to access CRISPR-based gene editing technology and RNA-targeted small molecule capabilities, expanding the company's platform beyond mRNA into gene editing and small molecule therapeutics. The acquisition was evaluated against alternative uses of capital and strategic priorities, with the board concluding that the technology provided competitive advantages.
Moderna acquired OriCiro Genomics for $85 million to access cell-free DNA amplification technology that improves the speed and efficiency of mRNA manufacturing, reducing production costs and increasing yields. The acquisition was evaluated against alternative uses of capital and strategic priorities, with the board concluding that the technology provided competitive advantages.
Moderna was founded in September 2010 as Moderna Therapeutics by Flagship Pioneering, the Cambridge, Massachusetts venture creation firm run by Noubar Afeyan. The founding team included Derrick Rossi, a stem cell biologist at Harvard Medical School who had demonstrated that modified mRNA could reprogram cells; Robert Langer, the prolific MIT biomedical engineer and inventor; Noubar Afeyan as chairman and primary backer; and Kenneth Chien, a cardiovascular researcher. The scientific vision was audacious: instead of delivering proteins directly as drugs, instruct the body's own cells to manufacture therapeutic proteins using synthetic messenger RNA. mRNA carries genetic instructions from DNA to ribosomes, where proteins are built. If you could deliver stable, modified mRNA into human cells, those cells would become temporary protein factories producing whatever therapeutic molecule you encoded. The concept built on foundational 2005 research by Katalin Karikó and Drew Weissman at the University of Pennsylvania, who demonstrated that chemically modifying mRNA nucleosides — replacing uridine with pseudouridine — reduced the immune system's inflammatory response to synthetic mRNA, making therapeutic use feasible. Karikó and Weissman would receive the 2023 Nobel Prize in Physiology or Medicine for this discovery. Moderna operated in stealth for its first two years, assembling a team of chemists, biologists, and engineers, filing foundational patents on modified mRNA formulations and lipid nanoparticle delivery systems, and building the manufacturing platform that would underpin every product it would ever develop.
Moderna emerged publicly in 2012 with a $40 million Series A financing, one of the largest biotech seed rounds at the time, signaling investor conviction in the mRNA platform despite its unproven clinical status. The early years involved landmark pharmaceutical partnerships that validated the technology and provided capital for platform development. In 2013, AstraZeneca signed an agreement worth up to $420 million to license Moderna's mRNA technology for cardiovascular and metabolic disease applications, providing both research funding and scientific credibility. In 2014, Merck entered a collaboration worth up to $450 million focused on personalized cancer vaccines, a partnership that would prove enormously consequential a decade later when the mRNA-4157 program emerged as a leading oncology candidate. These partnerships served multiple purposes: they provided non-dilutive capital that extended Moderna's runway, they exposed the technology to rigorous pharmaceutical industry testing, and they created commercial relationships that would later support product development. The company was simultaneously building its manufacturing platform, developing lipid nanoparticle formulations to protect and deliver mRNA into cells, and advancing early research programs across rare diseases, infectious diseases, and oncology. By 2018, with over $2 billion raised in private financing and a pipeline of more than 20 programs, Moderna pivoted its strategic focus from rare diseases — where its earlier programs had shown limited progress — to infectious disease vaccines, a decision that would prove transformative when COVID-19 emerged two years later.
When the SARS-CoV-2 genomic sequence was published on January 11, 2020, Moderna's team finalized the mRNA sequence for what would become mRNA-1273 within two days. The speed was possible because the mRNA platform required only a new genetic sequence — the manufacturing process, delivery system, and formulation were already established. The company shipped the first clinical batch to the National Institutes of Health on February 24, 2020, just 42 days after sequence selection, and the Phase 1 trial began in March 2020. This 63-day sequence-to-clinic timeline shattered all previous vaccine development records. The U.S. government's Biomedical Advanced Research and Development Authority provided $1.45 billion in funding in August 2020 to support late-stage development and manufacturing scale-up, one of the largest BARDA investments in history. The Phase 3 COVE trial enrolled 30,000 participants and demonstrated 94.1% efficacy against symptomatic COVID-19. The FDA granted Emergency Use Authorization on December 18, 2020 — just 11 months from sequence selection to authorization, a timeline previously considered impossible for vaccine development. Moderna's success validated the entire mRNA platform: if the technology could produce a 94%-efficacious vaccine against a novel pathogen in 11 months, the implications for future infectious disease outbreaks, cancer vaccines, and other therapeutics were transformative. The company's IPO in December 2018 at $23 per share, which had been controversial given its lack of approved products, ultimately looked prescient: the stock surpassed $400 in 2021 as COVID vaccine revenue materialized.
Moderna's revenue arc represents one of the most dramatic financial peaks and troughs in biotechnology history. The company generated essentially zero product revenue before 2021. In FY2021, Spikevax generated $17.7 billion in net product sales as governments worldwide procured COVID vaccines at emergency prices under advance purchase agreements. FY2022 revenue reached $18.4 billion, the peak, reflecting continued government procurement and booster campaigns. The decline began in FY2023 as pandemic emergency procurement shifted to endemic seasonal demand: revenue fell to $6.8 billion, a 63% drop in a single year. FY2024 revenue was $3.24 billion, and FY2025 revenue was $1.94 billion — a 40% further decline. The total collapse from peak to 2025 represents a 89% revenue decline over three years. The drivers were structural rather than temporary: governments drew down stockpiles built during the pandemic, vaccination rates in the endemic period dropped dramatically compared to pandemic mandates, and the market transitioned from government bulk procurement at $15-20 per dose to retail pharmacy sales with insurance reimbursement at lower effective prices. Moderna's cost structure, built for pandemic-scale production of billions of doses, proved difficult to shrink proportionally, creating large operating losses. The company reported a GAAP net loss of $2.822 billion in FY2025, and has executed a $2.2 billion operating expense reduction program. CEO Stéphane Bancel has guided the company toward a cash break-even target by 2028, supported by approximately $6 billion in cash and investments at year-end 2025.
Moderna has three approved products as of 2026: Spikevax, the original COVID-19 mRNA vaccine authorized December 2020; mNEXSPIKE, a next-generation COVID vaccine targeting the LP.8.1 variant approved in 2025, which captured approximately 24% of all U.S. retail COVID vaccinations in its first year; and mRESVIA, an RSV vaccine for adults 60 and older approved in 2024 and expanded to high-risk adults aged 18-59 in 2025. The broader pipeline includes more than 45 development programs. In respiratory vaccines, mRNA-1010 for seasonal influenza demonstrated 26.6% superior relative vaccine efficacy versus standard-dose flu vaccine in Phase 3, a statistically significant and clinically meaningful result that positions it for potential FDA approval in a $5 billion global market. A norovirus vaccine (mRNA-1403) is in Phase 3 with data expected in 2026. In oncology, mRNA-4157 — a personalized cancer vaccine that encodes patient-specific tumor neoantigens — has shown a 44% reduction in melanoma recurrence risk when combined with Merck's Keytruda in Phase 2, driving Phase 3 advancement with data expected in 2026-2027. The HIV mRNA program is in early clinical development. In rare diseases, programs targeting methylmalonic acidemia (mRNA-3704) and propionic acidemia (mRNA-3927) are advancing. A cytomegalovirus vaccine failed its Phase 3 primary endpoint in October 2025, representing a setback. Moderna has filed more than 100 peer-reviewed papers since 2018, establishing a scientific publication record that supports pipeline credibility and recruits top talent.